GSK latest Children's Flonase line extension could reach first-year sales as high as $75 million

PARSIPPANY, N.J. - GlaxoSmithKine on Thursday alerted customers that soon its allergy relief formula would be available in a children's strength as soon as March in an email. "Children lead busy lives — and need allergy relief," GSK stated. "Let parents know: Flonase Allergy Relief is indicated for children 4 and up, and is also available in the adult allergy section."

 

GSK's Flonase was clearly the top launch in 2015, garnering $294.3 million in its first 10 months on shelf, according to IRI data. And if sales of the children's liquid versions of existing allergy brands is any indication, sales of Children's Flonase could range anywhere from 10% to 25% on top of its parent brand. Already, that would mean first-year sales falling between $30 million and $75 million, and the parent brand isn't showning any signs of plateauing, yet, so the top end of that range could skew higher. 

 

And the instructions for use, seen below, are very clear - in line with other cough, cold and allergy products many members of the Consumer Healthcare Products Association voluntarily don't market their products to children under the age of four. For children between the ages of four and 11, GlaxoSmithKline recommends parents consult their pediatrician after two months of daily use per year.